Because of CBP’s remarkable effectiveness against NSCLC tumors exhibiting EGFR mutations and its potential as a substitute treatment for malignancies resistant to OSM, we chose CBP as the therapeutic chemotherapy model for our study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.